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Abstract Introduction: Arte-
mether-lumefantrine (AL), the 
most frequently prescribed ACTs 
for uncomplicated P. falciparum 
malaria, requires multiple doses  
which may militate against adher-
ence. It is necessary to evaluate 
the efficacy and safety of single 
dose ACT like Artemisinin-
naphthoquine (ANQ) to enhance 
adherence.  
Methods: This was an open label 
randomized controlled clinical 
trial. Eligible children were as-
signed to receive either a single 
dose of ANQ or six doses of AL 
following parental consent. A 
total of 108 children aged 5 – 14 
years with uncomplicated falcipa-
rum malaria were enrolled and 
assigned as follows: 58 (ANQ) 
and 50 (AL). Participants were 
observed for 28 days and clinical 
and parasitological assessments 
carried out. Outcomes were as-
sessed based on World Health 
Organization protocol.  
Results: A total of 97 patients 
completed the study. Overall 28-
day cure rate was 87.0% (47/54) 
and 81.4% (35/43) for ANQ and 
AL respectively. One patient 
(2.2%) in the AL group had Early 
Treatment Failure while seven 
(16.3%) had Late Parasitological 
Failure (LPF). LPF was also re-
ported in seven (13.0%) patients in 
the ANQ group. There was no 
Late Clinical Failure. A mild self-
limiting papular rash was noted in 
one child in ANQ group. There 
was no serious adverse event. 
Conclusions: The therapeutic effi-
cacies of ANQ and AL were com-
parable. A more robust, adequately 
powered, dose optimization study 
with PCR-confirmed parasitologi-
cal outcome measures is needed. 
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Introduction 
 
Malaria is still a major cause of childhood morbidity and 
mortality in sub-Saharan Africa with most cases being 
from Plasmodium falciparum (P. falciparum) infec-
tions1. The artemisinin combination therapies (ACTs) 
are currently first-line treatment for uncomplicated P. 
falciparum malaria with Artesunate-amodiaquine, Arte-
m e t h e r - l u m e fa n t r i n e  ( A L ) ,  A r t e s u n a t e -
mefloquine,Artesunate+Sulfadoxine-Pyrimethamine and
Dihydroartemisinin-piperaquine endorsed for deploy-
ment by the World Health Organization (WHO).2 
Full course therapy with these ACTs is for three days. 
AL is the most prescribed ACT globally and is adminis-
tered at 0, 8, 24, 36, 48 and 60 hours.3 The relative short 
half-life of the Artemisinin compound and the slow n-
set of action of Lumefantrine makes this complex dose 
schedule necessary for maximal parasite killing2. Com-
plex schedules of ACTs have been reported to contribute 
to poor treatment adherence, reduction in therapeutic 
efficacy and emergence of drug resistance3,4. Haile-
mariam et al5 in Ethiopia reported 74.5% adherence to 
AL while Mace et al6 reported 65% adherence to AL in 
Malawi with the under-fives being significantly less 
likely to adhere than those five years and above.  
 
To improve treatment adherence especially in children, 
there is need to evaluate new ACTs that are much easier 
to administer. Artemisinin-naphthoquine (ANQ) is a 
fixed dose combination that can either be administered 
as a single dose therapy or in two divided doses taken 
within a 12 hours period for uncomplicated P. falcipa-
rum malaria. The drug has been reported to be effica-
cious and safe in adult population but studies in children 
are limited.7,8 
This study aimed to evaluate the efficacy and safety of a 
single dose therapy of ANQ versus the six dose, three 
day therapy of AL in children aged 5 – 14 years with 
uncomplicated P. falciparum malaria in Calabar, Cross 




The primary outcome measures were Early Treatment 
Failure (ETF), Late Clinical Failure (LCF), Late Parasi-
tological Failure (LPF) and Adequate Clinical and para-
sitological Response (ACPR) as defined in Table 1. This
is based on WHO protocol for assessment of antimalar-
ial therapeutic efficacy9. The secondary outcome meas-




Subjects and Methods 
 
This was a randomized controlled clinical trial con-
ducted between June 2006 and July 2007 in Ikot-Ansa 
Primary Health Centre, in Calabar Municipality of Cross 
River State, Nigeria. Malaria transmission in the ar a is 
intense and perennial. Anopheles gambiense and 
Anopheles funestus are the predominant vectors while P. 
falciparum is the predominant parasite in the study 
area.10 
 
Sample size determination 
 
Sample size was based on the demonstration of 20% 
difference in the 28 day cure rate between ANQ and AL, 
at 95% confidence interval, 90% study power, a one-
tailed statistical analysis and 8% attrition rate.11From the 
above, a minimum of 50 participants were needed in 




Ethical clearance for this study was obtained from the 
Ethics Committee of the University of Calabar Teaching 
Hospital. Informed consent was obtained from the par-




Basic demographic and clinical information was ob-
tained from children suspected to have uncomplicated 
malaria. This was followed by a general physical exami-
nation, anthropometric measurements and systemic ex-
amination. Thin and thick blood films for malaria pra-
site speciation and quantification as well as blood f r 
Packed Cell Volume (PCV) estimation were performed 




Children aged 5 - 14 years with history of fever in the 
past 24 hours or temperature ≥ 37.5oC on presentation, 
P. falciparum mono-infection, parasite density of 1,000 
– 200,000/µl of blood were considered eligible for inclu-
sion while those with history of ingestion of antimalarial 
two weeks prior to the study, haematocrit< 15%, fea-
tures of severe acute illnesses or chronic illnesses w re 
excluded from the study.   
 
Randomization of participants 
 
Patients were randomized using a block randomization 
echnique. They were then assigned into one of two 
treatment arms using an unpredictable allocation se-
quence that was generated by balloting.The sequence 
was concealed in brown sequentially labeled opaque 
envelope until intervention was assigned.13 Patients’ 
enrollment and implementation of the randomization 




The investigational products were Artemether-
lumefantrine (AL) (Coartem®), 20mg Artemether + 
120mg lumefantrine (Novartis Pharma, Switzerland) and
Artemisinin-naphthoquine (ARCO®), 125mg Artemisi-
nin + 50mg Naphthoquine (Kunming Pharmaceuticals 
Corp (KPC), China). The drugs were obtained from the 
manufacturers through one of their reputable wholesale/
retail outlets in Calabar. The batch number, manufact re 
and expiry dates were verified. The drugs were stored in 
a cabinet at room temperature of 20oC – 30oC. 
 
Treatment and follow-up 
 
The treatment was administered by the study nurse 
based on the body weight of the children. Those as-
signed to receive AL had six doses of the drug over 
three days while those assigned to ANQ had a single 
dose therapy2,7. The children were observed for at least 
30 minutes by the study nurse after drug administrat on. 
Those that vomited within this period were retreated. 
Those assigned to AL whose parents could not come t 
the health facility for subsequent therapies were visited 
and treated at home by a member of the study team. 
Children with temperatures above 38oC were lightly 
dressed, tepid sponged and given Paracetamol at a dose 
of 15 mg/kg. 
The children were followed up for 28 days. Parents were 
asked to bring the children to the facility on days 1, 2, 3, 
7, 14 and 28. The wellbeing of the children, assessm nt 
of side effects of the drugs and blood smears for malaria 
parasite were performed on those days while haema-
tocrit estimation was done on days 0, 3, 14 and 28.  
 
Statistical analysis  
 
Data generated were recorded in the patients’ case report 
form, validated and entered into STATA version 10 for 
analysis. The results were presented as text, flow chart 
and tables. Clinical and parasitological outcome meas-
ures were assessed based on WHO protocol (Table 1). 
‘Per protocol’ analysis was used to assess patients with 
evaluable outcomes. Student’s t- test was used to deter-
mine the difference in mean between two continuous 
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variables while chi-square (ᵡ2) test was used to test for 
association between categorical variables. 
 





































Nine hundred and fifty five children were screened for 
eligibility and 847 excluded. Of the 108 children re-
cruited, 58 were randomized to receive Artemisinin-
naphthoquine (ANQ) while 50 were to receive Arte-
mether-lumefantrine (AL). In ANQ group, 54 (93.1%) 
children completed the study as against 43 (86.0%) in 
AL group. The study profile is shown in Figure 1. The 
baseline characteristics of participants in both arms of 
the study were comparable (Table 2). 
 
Table 2: Baseline characteristics of participants 
at-test for two independent groups 
bMann-Whitney test 
 
Comparison of the therapeutic efficacy of ANQ and AL 
 
Of the 54 children that completed treatment with ANQ, 
47 (87.0%) had Adequate Clinical and Parasitological 
Response (ACPR) while 7 (13.0%) had Late Parasi-
tological Failure (LPF). There was no report of Late 
Clinical Failure (LCF). In the AL group 35 (81.4%) had 
ACPR, 7 (16.3%) had LPF while 1 (2.2%) had Early 
Treatment Failure (ETF) as shown in Table 3.   
 




A generalized maculopapular rash which cleared sponta-
neously within three days in a child treated with ANQ. 
This was the only clinical adverse event reported in the 





The study showed that the therapeutic effi.cacy of a sin-
 Terms                    Definition 
Early Treatment 
Failure (ETF) 
This is the development of danger signs of 
severe illness or severe malaria on Days 1, 2 or 
3 in the presence of parasitaemia, or parasitae-
mia on Day 2 higher than Day 0 count irrespec-
tive of axillary temperature, or parasitaemia on 
Day 3 with axillary temperature ≥ 37.5oC, or 
parasitaemia on Day 3 > 25% of Day 0 count 





This is defined as development of danger signs 
or severe malaria and /or axillary temperature ≥ 
37.5oC on any day from Day 4 to Day 28 in the 
presence of parasitaemia without previously 







This is defined as the presence of parasitaemia 
from Day 4 to Day 28 and axillary temperature 
< 37.5oC without previously meeting any of the 








This is defined as absence of parasitaemia on 
Day 28 irrespective of axillary temperature 
without previously meeting any of the criteria 
of Early Treatment Failure, Late Clinical Fail-










Completed trial =54 Completed trial = 43 
847 excluded mostly due to 
parasite density < 1 000 /µl 
Lost to fol-
low-up = 2 
With-











Age (years) 7.48 (0.36)  7.54 (0.32) 0.9068a 
Weight  (Kg) 25.45 (1.30) 23.648 (0.366 
(0.93) 
0.2788a 
Height  (cm) 124.8 (2.61) 123.7 (1.75) 0.7177a 
Packed cell volume Day 0 31.67 (0.53) 33.15 (0.54) 0.0552a 
Axillary Temperature (oC) 







Geometric mean (95% 
CI) 
parasite density in µL 









      ANQ (54 patients) AL  (43 
patients) 
  No % No % 
Early Treatment Failure 0 0 1 2.2 
Late Clinical Failure 0 0 0 0 
Late Parasitological Failure 7 13.0 7 16.3 
Adequate Clinical and Parasi-
tological Response 
 47 87.0 35 81.4 
gle dose therapy of Artemisinin-naphthoquine (ANQ) 
was comparable to the six-dose, three-day therapy of 
Artemether-lumefantrine (AL) for treatment of uncom-
plicated P. falciparum malaria in the children. Since 
these parasitological findings were not confirmed by 
polymerase chain reaction (PCR) it is possible thate 
28-day “per protocol” cure rates (ACPR) of 87.0% and 
81.4% recorded for ANQ and AL respectively were in-
fluenced by new infections which could not be clinially 
distinguished from recrudescent cases. New infections 
are known to occur within 28 days of treatment even 
with an efficacious antimalarial regimen. This is more 
common in areas of high malaria transmission9. Given 
that the location of the current study is characterized by 
high and perennial malaria transmission; it is likely that 
a proportion of the late parasitological failures rcorded 
in this study were due to new infections instead of recru-
descence. In a non-comparative evaluation of AL among 
infants and children from three African countries includ-
ing Nigeria, Falade et al14 reported a day 28 PCR-
uncorrected cure rate of 86.5% which was adjusted to 
93.9% when PCR correction for re-infection was per-
formed. 
 
It is noteworthy that the therapeutic efficacy of AL re-
corded in this study is lower than what had been earlier 
reported in the study area15. The fact that it has not been 
possible in this study to ascertain whether cure rat s 
observed for either of the compounds used in the present 
study were due to treatment failures or new infections 
makes the notion on non-inferiority of these ACT regi-
mens inconclusive. The study however adds to the body 
of literature on the effectiveness of single-dose ANQ 
and its potential role as alternative treatments in cases of 
treatment failures with currently recommended Artemis-
inin combination treatment regimens.  
 
In the light of recent reports in decline of efficacy of 
Artemisinin compounds in Southeast Asia16 it is justifi-
able to express the concern that the observed treatment 
failures in the present Nigerian study may be indicative 
of a decline in parasite susceptibility to Artemisin n 
compounds in the study area. It is worthy of note that 
this report of apparent decline in artemisinin efficacy is 
incidentally made in the same part of Nigeria where 
Chloroquine-resistant P. falciparum malaria was first 
documented in the country.17 
 
The difference in the ACPR between ANQ and AL may 
likely be due to the nature of the partner drugs since 
both have an artemisinin compound as base. The six 
dose regimen of AL given over three days has been 
shown in clinical trials and a Cochrane systematic re-
view to be more efficacious than the four dose regi-
men.18 Based on the fact that increasing frequency of 
administration of the artemisinins is associated with an 
increase in cure rate, the six dose regimen of AL was 
expected to achieve a higher cure rate than the single 
dose of ANQ. The reverse was rather the case in this 
study. This seeming paradoxical result may be attributed 
to the pharmacokinetic and pharmacodynamic differ-
ences between Naphthoquine and Lumefantrine.  
Naphthoquine (NQ) is a compound that is rapidly and 
completely absorbed after oral administration with a 
relative bioavailability of 96.4% that is independet of 
the nature of meal the patient takes.8 The high bioavail-
ability of the drug makes for a thorough killing of vari-
ous schizonts of plasmodia unlike lumefantrine which 
requires fatty meals to enhance its digestion and absorp-
tion.19 Since children with uncomplicated malaria are 
usually anorexic, there is a likelihood that poor absorp-
tion with sub-optimum plasma concentration of the drug 
might have contributed to the relatively low efficacy of 
AL.19 
 
There was no record of an Early Treatment Failure 
(ETF) in children treated with ANQ but this event was 
reported in a child who received AL. The child had fever 
on day three and persistent parasitaemia on day 3 of the 
study. The ACTs are known to rapidly reduce parasite 
biomass and resolve clinical symptoms within 48 hours 
of administration4. ETF connotes a clinical or parasi-
tological progression in disease severity within the first 
three days of initiation of the antimalarial therapy.9 
This is the first report of an ETF with AL in the study 
area. The 2009 drug therapeutic efficacy trial conducted 
among under-fives with uncomplicated malaria in nine 
malaria sentinel sites in the country which compared AL 
with Artesunate-amodiaquine (AA) reported a PCR-
uncorrected cure rate of 95.7% – 99. 5% with AA and 
96.3% - 99.2% with AL. ETF was reported in one child 
in the survey that was treated with AA.20 The finding of 
ETF with AL in this study may therefore be a warning 
signal concerning the possible emergence of high level 
of parasite resistance to the drug. 
 
The only clinical adverse event recorded in this study 
was generalized papular rash which cleared spontane-
ously within three days in a child treated with ANQ. 
Nausea, vomiting and diarrhea have been reported for 
both drugs, cough and anaemia were reported with the 
use of AL14 while dizziness and pruritus were noted with 
the use of ANQ.10 
 
ANQ may have a programmatic advantage over AL be-
ing a single dose therapy. The ease of its administration 
enhances adherence to treatment and so will prevent th  
likely occurrence of drug resistance. Busy and lessedu-
cated caregivers of sick children will find a single dose 
therapy of ANQ convenient. This therefore makes ANQ 
a potential drug for deployment as first-line therapy for 
uncomplicated P. falciparum malaria in endemic re-
gions. The inability to perform a PCR-correction to as-
certain possibility of reinfection is acknowledged as a 
limitation that could have an influence on the interpr ta-





The efficacy of a single dose therapy of ANQ is quite 
comparable to the 6 dose therapy of AL in the treatm nt 
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